Fueling an Epidemic: Inside the Insys Strategy for Boosting Fentanyl Sales

Loading...
Thumbnail Image
Serial Number
Levin Center Identifier
Document Date
2018-10-17
Report Length
193 pages
Policy Agendas Project Major Code
Additional, Minority, Dissenting Views
Found Using Methodology
Yes
Subcommittee(s)
Commission(s)
Idependent Author(s)
Brief Executive Summary
The Senate Committee on Homeland Security and Governmental Affairs, on behalf of Ranking Member Claire McCaskill, issued a Minority Staff report discussing how the interplay between compensation, for physicians and their sales representatives, drove massive growth for Insys Therapeutics Inc., as it established sales and marketing practices to boost Subsys (Fentanyl) sales. The report published its findings as a warning to policymakers seeking to prevent actors in the pharmaceutical industry from driving the next public health crisis. The report found that Insys executives emphasized the importance of “owning” a physician, through promises of compensation for both sides, which has significantly affected patient treatment. The report concluded that Insys fostered a scheme to profit by utilizing bribes and fraud to contribute to the illicit distribution of Subsys.
Press Releases and Contextual Information
Related Hearings
Authors–Congress Members
Authors–Staff Members
Authors–Ex Officio Members
Authors–Additional, Minority, Dissenting Views
Citation